Reyataz label
Interaction Color Code
Clinical Bottom Line
Adjust dosing to avoid reduced levels of atazanavir
Drug 1
Drug 1 dose
400 mg daily on d 1-12 (simultaneous administration)
Drug 1 effect
Atazanavir AUC decreased 41%, Cmax decreased 47%, Cmin decreased 42%
Drug 2
Drug 2 dose
40 mg BID on d 7-12
Clinical Effects
Potential loss of antiretroviral efficacy
Management
Unboosted atazanavir: administer dose 2 hrs before or 10 hours after the H2-blocker. H2 blocker single dose should not exceed 20 mg famotidine and total daily dose should not exceed 40 mg famotidine (treatment naive patients). Ritonavir or cobicistat boosted atazanavir: administer dose simultaneously with or > 10 hours after H2 blocker. Do not exceed H2 blocker doses of 80 mg famotidine daily (treatment naive) or 40 mg famotidine daily (treatment experienced). If using in a treatment-experienced patient who is also on TDF, increase atazanavir dose to 400 mg with boosting.
Import ID
795
